Ranolazine, a partial fatty acid oxidation inhibitor, its potential benefit in angina and other cardiovascular disorders

Recent Patents on Cardiovascular Drug Discovery

Volumn 2, Issue 1, 2007, Pages 35-39

  Bhandari, Bharti ^a   Subramanian, L ^a  

^a MANAV RACHNA INTERNATIONAL INSTITUTE OF RESEARCH AND STUDIES   (India)

Author keywords

Chronic angina; Fatty acid oxidation inhibitor; Myocardial ischemia; Reactive oxygen species

Indexed keywords

AMLODIPINE; ANTIANGINA PECTORIS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; FATTY ACID; GLUCOSE; GLYCERYL TRINITRATE; KETOCONAZOLE; METOPROLOL; NITRATE; OXYGEN; PLACEBO; RANOLAZINE; REACTIVE OXYGEN METABOLITE; SIMVASTATIN; TRIMETAZIDINE; VASODILATOR AGENT; VERAPAMIL;

ABDOMINAL PAIN; ANGINA PECTORIS; ASTHENIA; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CELL METABOLISM; CHRONIC DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DIZZINESS; DRUG APPROVAL; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG STRUCTURE; DYSPEPSIA; ENERGY METABOLISM; FATTY ACID OXIDATION; FOOD AND DRUG ADMINISTRATION; GLUCOSE OXIDATION; HEADACHE; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HUMAN; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; QT INTERVAL; REPERFUSION; REVIEW; SYNCOPE; TABLET; UNITED STATES;

ACETANILIDES; ANGINA PECTORIS; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; FATTY ACIDS; HEART FAILURE; HUMANS; OXIDATION-REDUCTION; PIPERAZINES;

EID: 34249330333     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489007779606095     Document Type: Review

References (54)

1. Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischemic heart disease, a novel approach to treatment. Eur Heart J 2004; 25: 634-41.
2. Szwed H. Clinical benefits of trimetazidine in patients with recurrent angina. Coron Artery Dis 2004; 15 Suppl 1: S17-21.
3. Chaitman BR. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation 2006; 113: 2462-72.
4. Wolff AA, Rotmensch HH, Stanley WC, Ferrari R. Metabolic approaches to the treatment of ischemic heart disease: the clinicians' perspective. Heart Fail Rev 2002; 7: 187-203.
5. Peter Berger. Ranolazine and other anti-anginal therapies in the era of the drug-eluting stent. JAMA 2004; 291: 365-367.
6. Cobbe S. Electrophysiological perspectives - what has ranolazine taught us? Eur Heart J 2004; 6: 9-11.
7. McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 1996; 93: 135-42.
8. Mahesh Kumar KN, Sandhiya S. Ranolazine: A novel partial inhibitor of fatty acid oxidation for angina. Indian J Pharmacol 2006; 38: 302-304.
9. Makielski JC & Valdivia CR. Ranolazine and late cardiac sodium current - a therapeutic target for angina, arrythmia and more. Brit J Pharmacol 2006; 148: 4-6.
10. Paul F. Kantor, Arnaud Lucien, Raymond Kozak, Gary D. Lopaschuk. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A. Circ Res 2000; 86; 580-588.
11. Jackson G. Haemodynamic and metabolic agents in the treatment of stable angina: publication review. Coron Artery Dis 2001; 12 Suppl 1: S22-4.
12. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004; 110(8): 904-910.
13. Schram G, Zhang L, Derakhchan Y, Ehrlich JR, Belardinelli L, Nattel S. Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects. Br J Pharmacol 2004; 142(8): 1300-1309.
14. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 2006; 92 Suppl 4: iv6-ivl4.
15. Gambert S, Vergely C, Filomenko R, et al. Adverse effects of free fatty acid associated with increased oxidative stress in postischemic isolated rat hearts. Mol Cell Biochem 2006; 283(1-2): 147-152.
16. Jerling M. Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet 2006; 45(5): 469-91.
17. Liu XD, Xie L, Liang Y, Li L, Lu T. Gender difference in ranolazine pharmacokinetics in rats. Eur J Drug Metab Pharmacokinet 2003; 28(2): 119-23.
18. Jerling M, Abdallah H. Effect of renal impairment on multipledose pharmacokinetics of extended-release ranolazine. Clin Pharmacol Ther 2005; 78: 288-97.
19. Jerling M, Huan BL, Leung Y,, Chu N, Abdallah H, Hussein Z. Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol 2005; 45: 422-33.
20. Gaffney SM. Ranolazine, a novel agent for chronic stable angina. Pharmacotherapy 2006; 26: 135-142.
21. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004; 43: 1375-1382.
22. Antzelevitch C, Belardinelli L, Wu L, et al. Electrophysiologic properties and antiarrhythmic actions of a novel andanginal agent. J Cardiovasc Pharmacol Ther 2004; 9 Suppl 1: S65-83.
23. Szwed H. Clinical benefits of trimetazidine in patients with recurrent angina. Coron Artery Dis 2004; 15 Suppl 1: S17-21.
24. Vitale C, Wajngaten M, Sposato B, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. For Heart J 2004; 25(20): 1814-1821.
25. Shlyakhto EV, Almazov VV, Nifontov EM, et al. Antianginal effects of trimetazidine and left ventricular function improvement in patients with stable angina pectoris. Am J Cardiovasc Drugs 2002; 2(2): 119-24.
26. Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev 2005; (4): CDO03614.
27. Chaitman BR, Pepine CJ, Parker JO, et al. Combination assessment of ranolazine in stable angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomised controlled trial. JAMA 2004; 291: 309-16.
28. Stone PH, Gratsiansky NA, Blokbin A, Huang I, Meng L. On behalf of the ERICA investigators. Antianginal efficacy of ranolazine when added to maximal treatment with convensional therapy: the efficacy of ranolazine in chronic angina trial. Circulation 2005; 112: II-748.
29. Luscher T. Future directions in the management of chronic angina and ACS - the MERLIN-TIMI 36 trial. Eur Heart J 2004; 6: 17-18.
30. Heinrich T. Cardiac metabolism as a target for the treatment of heart failure. Circulation 2004; 110: 894-896.
31. Goodwin GW, Taylor CS, Taegtmeyer H. Regulation of energy metabolism of the heart during acute increase in heart work. J Biol Chem 1998; 273: 29530-29539.
32. Doenst T, Goodwin GW, Cedars AM, et al. Load-induced changes in vivo alter substrate fluxes and insulin responsiveness of rat heart in vivo. Metabolism 2001; 50: 1083-1090.
33. Taegtmeyer H, Sharma S, Golfman L, et al. Linking gene expression to function: metabolic flexibility in normal and diseased heart. Ann N Y Acad Sci 2004; 1015: 1-12.
34. Stanley WC, Chandler MP. Energy metabolism in the normal and failing heart: potential for therapeutic interventions. Heart Fail Rev 2002; 7: 115-130.
35. Sharov VG, Goussev A, Lesch M, Goldstein S, Sabbah HN. Abnormal myocardial function in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol 1998; 30: 1757-1762.
36. Paolisso G, Gambardella. A, Galzerano D, et al. Total-body and myocardial substrate oxidation in congestive heart failure. Metabolism 1994; 43: 174-179.
37. Hermann HP, Pieske B, Schwarzmuller E, Keul J, Just H, Hasenfuss G. Haemodynamic effects of intracoronary pyruvate in patients with congestive heart failure: an open study. Lancet 1999; 353: 1321-1323.
38. Bersin RM, Wolfe C, Kwasman M, et al. Improved haemodynamic function and mechanical efficiency in congestive failure with sodium dichloroacetate. J Am Coll Cardiol 1994; 23: 1617-1624.
39. Margaret PC, William CS, Hideaki M, et al. Short - term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. Circ Res 2002; 91: 278-80.
40. Taegtmeyer H. Energy metabolism of the heart: from basic concepts to clinical applications. Curr Prob Cardiol 1994; 19: 57-116.
41. M Faadiel Essop, Lionel H Opie. Metabolic therapy for heart failure. Eur Heart J 2004; 25: 1765-1768.
42. Luiz Belardinelli, John CS, aheather F. The mechanism of ranolazine action to reduce ischemia induced diastolic dysfunction. Eur Heart J Supp 2006; 8: A 10-13.
43. Thrainsdottir I, VonBibra H, Malmberg K, Rydes L. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006; 48(5): 992-98.
44. Fragasso G, Palloshi A, Puccetti P et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine / adenosine triphosphate ratio in patients with heart failure. Eur Heart J 2006; 27(8): 942-48.
45. Foley JE. Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus. Diabetes Care 1992; 15(60): 773-784.
46. Hanna S, Zygmunt S, Robert P, et al. Proposed antiischemic effects of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-1. Cardiovasc Drugs & Therapy 1999; 13(3): 217-222.
47. Fragasso G, Piatti Md PM, Monti L, et al. Short and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J 2003; 146(5): E18.
48. Thrainsdottir IS, Von Bibra H, Malmberg K, Ryder L. Effects of trimetazidine on left ventricular function in patients with type 2 Diabetes and heart failure. J Cardiovasc Pharmacol 2004; 44(1): 101-108.
49. Rasano GM, Vitale C, Sporato B, Mercuro G, Fini M. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol 2003; 2: 16.
50. Andrew, A.W., Brent, B.: CN1227004C (2005).
51. Wolff, A.A., Blackburn, B., Sabbah, H., Naief, S.W.C.: NZ0520780A ( 2005).
52. Guangfu, L.Y.: CN1248690C (2006).
53. Wolff, A.A., Baker, F.L., John, R.: US20060217397A1 (2006).
54. FDA labelling information, 2006.